OM
XERS icon

Opaleye Management’s Xeris Biopharma Holdings XERS Stock Holding History

Opaleye Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-390,000
Closed -$725K – 52
2023
Q3 		$725K Buy
+390,000
New +$893K 0.24% 37

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management's XERS Position: Q4 2023 in Review

Opaleye Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2023, closing a stake of 390,000 shares — an estimated $725K sold.

Opaleye Management first reported a position in XERS in Q3 2023 and held it in 1 quarter. The position peaked at $725K in Q3 2023. 120 funds tracked by Wall St. Rank hold XERS as of Q4 2023.

  • Opaleye Management reported no remaining Xeris Biopharma Holdings position as of Q4 2023 after selling out during the quarter.
  • Opaleye Management sold 390,000 Xeris Biopharma Holdings shares in Q4 2023, an estimated $725K.
  • Opaleye Management first reported a position in Xeris Biopharma Holdings in Q3 2023 and held it in 1 quarter.
  • Opaleye Management's Xeris Biopharma Holdings position peaked at $725K in Q3 2023.
  • 120 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2023.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.